-
1.发明授权
公开(公告)号：US5891628A
公开(公告)日：1999-04-06
申请号：US460751
申请日：1995-06-02
CPC分类号： C07K14/47 , C12Q1/6883 , A01K2217/05 , A61K38/00 , C12Q2600/156 , C12Q2600/158
摘要： The present invention relates to the identification of the autosomal dominant polycystic kidney disease (PKD) gene and high throughput assays to identify compounds that interfere with PKD activity. Interfering compounds that inhibit the expression, synthesis and/or bioactivity of the PKD gene product can be used therapeutically to treat polycystic kidney disease.
摘要翻译： 本发明涉及常染色体显性多囊肾病（PKD）基因的鉴定和高通量测定以鉴定干扰PKD活性的化合物。 抑制PKD基因产物的表达，合成和/或生物活性的干扰化合物可用于治疗性治疗多囊肾病。
-
公开(公告)号：US06395877B1
公开(公告)日：2002-05-28
申请号：US09261599
申请日：1999-02-26
IPC分类号： C07K100
CPC分类号： C07K14/705 , C07K14/723
摘要： The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders, specifically, cardiovascular diseases, including congestive heart failure. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.
摘要翻译： 本发明涉及属于G蛋白偶联受体的超家族的新鉴定的受体。 本发明还涉及编码受体的多核苷酸。 本发明还涉及使用受体多肽和多核苷酸作为受体介导的障碍，特别是心血管疾病包括充血性心力衰竭的诊断和治疗的靶标的方法。 本发明还涉及使用受体多肽和多核苷酸鉴定用于诊断和治疗的激动剂和拮抗剂的药物筛选方法。 本发明还包括基于受体多肽和多核苷酸的激动剂和拮抗剂。 本发明还涉及产生受体多肽和多核苷酸的方法。
-
3.发明申请Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor 失效小分子25869,25934,26335,5049,21117,38692,46508,16816,16839,49937,49931和49933分子及其用途公开(公告)号：US20080241133A1
公开(公告)日：2008-10-02
申请号：US12150094
申请日：2008-04-24
申请人： Rory A. J. Curtis , Thomas Joseph Logan , Maria Alexandra Glucksmann , Rachel E. Meyers , Mark J. Williamson , Laura A. Rudolph-Owen , Miyoung Chun , Fong-Ying Tsai
发明人： Rory A. J. Curtis , Thomas Joseph Logan , Maria Alexandra Glucksmann , Rachel E. Meyers , Mark J. Williamson , Laura A. Rudolph-Owen , Miyoung Chun , Fong-Ying Tsai
IPC分类号： A61K39/395 , C12N15/11 , C12N5/06 , C07K14/00 , C07K16/18 , A61K31/70 , A61P43/00 , C12P21/04 , G01N33/566 , C12Q1/68 , A61K38/00
CPC分类号： C07K14/705 , A01K2217/05 , A61K38/00 , C07K14/395 , C07K14/43545 , C07K14/43581 , C07K14/43595 , C07K14/463 , C07K14/465 , C07K14/47 , C07K2319/00 , C12N9/00 , C12N9/0071 , C12N9/0083 , C12N9/1205 , C12N9/18 , C12N9/20 , C12N9/88 , C12N2310/3513 , C12Y207/01001 , C12Y301/04003
摘要： The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译： 本发明提供分离的核酸分子，命名为25869,25934,26335,50516,21117,38692,46508,16816,16839,49937,49931和49933核酸分子。 本发明还提供反义核酸分子，包含25869,25934,26335,50521,21117,38692,46508,16816,16839,4467,49931或49933核酸分子的重组表达载体，已经引入了表达载体的宿主细胞 ，以及引入或破坏25869,25934,26335,50365,21117,38692,46508,16816,16839,49937,49931或49933基因的非人转基因动物。 本发明还进一步提供了分离的25869,2593,26335,50365,21117,38692,46508,16816,16839,49937,49931或49933蛋白，融合蛋白，抗原肽和抗-25869,25934,26335,50365,211117,38692 ，46508,16816,16839,49937,49931或49933抗体。 还提供了利用本发明组合物的诊断和治疗方法。
-
公开(公告)号：US06767727B2
公开(公告)日：2004-07-27
申请号：US10314881
申请日：2002-12-09
IPC分类号： C12N916
摘要： The present invention relates to newly identified human sulfatases. In particular, the invention relates to sulfatase polypeptides and polynucleotides, methods of detecting the sulfatase polypeptides and polynucleotides, and methods of diagnosing and treating sulfatase-related disorders. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules.
摘要翻译： 本发明涉及新鉴定的人类硫酸酯酶。 特别地，本发明涉及硫酸酯酶多肽和多核苷酸，检测硫酸酯酶多肽和多核苷酸的方法，以及诊断和治疗硫酸酯酶相关病症的方法。 还提供了用于制备和使用新分子的载体，宿主细胞和重组方法。
-
公开(公告)号：US20090275050A1
公开(公告)日：2009-11-05
申请号：US12384953
申请日：2009-04-10
IPC分类号： G01N33/567 , C12Q1/00 , C12Q1/44 , C12Q1/02 , C12N9/00 , G01N33/566 , G01N33/536 , G01N33/68 , C07K16/28 , C07K16/46
CPC分类号： C07K14/723
摘要： The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders, specifically, cardiovascular diseases, including congestive heart failure. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.
-
公开(公告)号：US07057028B2
公开(公告)日：2006-06-06
申请号：US10077698
申请日：2002-02-13
IPC分类号： C07H21/04 , C07H1/00 , C12N1/20 , C12P21/02 , G01N33/567
CPC分类号： C07K14/723 , C07K14/705
摘要： The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders, specifically, cardiovascular diseases, including congestive heart failure. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.
摘要翻译： 本发明涉及属于G蛋白偶联受体的超家族的新鉴定的受体。 本发明还涉及编码受体的多核苷酸。 本发明还涉及使用受体多肽和多核苷酸作为受体介导的障碍，特别是心血管疾病包括充血性心力衰竭的诊断和治疗的靶标的方法。 本发明还涉及使用受体多肽和多核苷酸鉴定用于诊断和治疗的激动剂和拮抗剂的药物筛选方法。 本发明还包括基于受体多肽和多核苷酸的激动剂和拮抗剂。 本发明还涉及产生受体多肽和多核苷酸的方法。
-
公开(公告)号：US06972187B2
公开(公告)日：2005-12-06
申请号：US10154419
申请日：2002-05-22
IPC分类号： A61K38/00 , A61K48/00 , C07K14/47 , C07K14/705 , C12N9/14 , C12N9/16 , G01N33/50 , G01N33/68 , C12N15/00 , C07H21/04 , C12N1/21 , C12N15/63 , C12N15/85
CPC分类号： C12N9/16 , A01K2217/05 , A01K2217/075 , A61K38/00 , A61K48/00 , C07K14/47 , C07K14/4702 , C07K14/705 , C07K2319/00 , C12N9/14 , C12N2310/3181 , C12N2310/351 , G01N2500/02 , G01N2500/04 , G01N2500/10 , G01N2500/20
摘要： The invention provides isolated nucleic acids molecules, designated OAT5 nucleic acid molecules, which encode organic anion transporters. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing OAT5 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a OAT5 gene has been introduced or disrupted. The invention still further provides isolated OAT5 polypeptides, fusion polypeptides, antigenic peptides and anti-OAT5 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译： 本发明提供编码有机阴离子转运蛋白的分离的核酸分子，称为OAT5核酸分子。 本发明还提供了反义核酸分子，含有OAT5核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，以及其中导入或破坏了OAT5基因的非人转基因动物。 本发明还进一步提供了分离的OAT5多肽，融合多肽，抗原肽和抗OAT5抗体。 还提供了利用本发明组合物的诊断和治疗方法。
-
公开(公告)号：US06448005B1
公开(公告)日：2002-09-10
申请号：US09456455
申请日：1999-12-08
IPC分类号： C07K100
CPC分类号： C07K14/705 , C07K14/723
摘要： The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders, specifically, cardiovascular diseases, including congestive heart failure. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.
摘要翻译： 本发明涉及属于G蛋白偶联受体的超家族的新鉴定的受体。 本发明还涉及编码受体的多核苷酸。 本发明还涉及使用受体多肽和多核苷酸作为受体介导的障碍，特别是心血管疾病包括充血性心力衰竭的诊断和治疗的靶标的方法。 本发明还涉及使用受体多肽和多核苷酸鉴定用于诊断和治疗的激动剂和拮抗剂的药物筛选方法。 本发明还包括基于受体多肽和多核苷酸的激动剂和拮抗剂。 本发明还涉及产生受体多肽和多核苷酸的方法。
-
9.发明申请Novel nucleic acid sequences encoding adenylate kinases, alcohol dehydrogenases, ubiquitin proteases, lipases, adenylate cyclases, and GTPase activators 审中-公开编码腺苷酸激酶，醇脱氢酶，泛素蛋白酶，脂肪酶，腺苷酸环化酶和GTP酶激活剂的新型核酸序列公开(公告)号：US20090280482A1
公开(公告)日：2009-11-12
申请号：US12001737
申请日：2007-12-12
CPC分类号： C12N9/6472
摘要： The invention provides isolated nucleic acids molecules that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
摘要翻译： 本发明提供编码新多肽的分离的核酸分子。 本发明还提供了反义核酸分子，含有本发明的核酸分子的重组表达载体，已经引入了表达载体的宿主细胞，以及本发明的序列已被引入或破坏的非人类转基因动物。 本发明还进一步提供分离的蛋白质，融合蛋白，抗原肽和抗体。 还提供了利用本发明组合物的诊断方法。
-
10.发明申请Novel TWIK-6, TWIK-7, IC23927, TWIK-8, IC47611, IC47615, HNMDA-1, TWIK-9, alpha2delta-4, 8099, 46455, 54414, 53763, 97076, 97102, 44181, 67084Fl and 67084alt molecules and uses therefor 审中-公开新颖的TWIK-6，TWIK-7，IC23927，TWIK-8，IC47611，IC47615，HNMDA-1，TWIK-9，α2delta-4,8099,46455,5414,53763,97076,97102,44181,67084F1和67084altalt分子， 用它公开(公告)号：US20080032289A1
公开(公告)日：2008-02-07
申请号：US11050947
申请日：2005-02-04
IPC分类号： C07K14/435 , C07K16/18 , C12N1/00 , C12N15/12 , C12N15/63 , C12N5/00 , C12P21/02 , C12Q1/68 , G01N33/53 , G01N33/68
CPC分类号： G01N33/57415 , A01K2217/05 , A01K2217/075 , A61K38/00 , C07K14/705 , C07K16/18 , C07K2319/00 , G01N33/57419 , G01N33/57423 , G01N33/57434 , G01N33/6872 , G01N2800/32 , G01N2800/325 , Y10T436/143333
摘要： The invention provides isolated nucleic acids molecules, designated TWIK-6, TWIK-7, IC23927, TWIK-8, IC47611, IC47615, HNMDA-1, TWIK-9, α2δ-4, 8099, 46455, 54414, 53763, 97076, 97102, 44181, 67084FL and 67084alt nucleic acid molecules, which encode novel ion channel family molecules, including calcium channels, potassium channels, and NMDA receptors. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing TWIK-6, TWIK-7, IC23927, TWIK-8, IC47611, IC47615, HNMDA-1, TWIK-9, α2δ-4, 8099, 46455, 54414, 53763, 97076, 97102, 44181, 67084FL and 67084alt nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a TWIK-6, TWIK-7, IC23927, TWIK-8, IC47611, IC47615, HNMDA-1, TWIK-9, α2δ-4, 8099, 46455, 54414, 53763, 97076, 97102, 44181, 67084FL and 67084alt gene has been introduced or disrupted. The invention still further provides isolated TWIK-6, TWIK-7, IC23927, TWIK-8, IC47611, IC47615, HNMDA-1, TWIK-9, α2δ-4, 8099, 46455, 54414, 53763, 97076, 97102, 44181, 67084FL and 67084alt polypeptides, fusion polypeptides, antigenic peptides and anti-TWIK-6, TWIK-7, IC23927, TWIK-8, IC47611, IC47615, HNMDA-1, TWIK-9, α2δ-4, 8099, 46455, 54414, 53763, 97076, 97102, 44181, 67084FL and 67084alt antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译： 本发明提供分离的核酸分子，称为TWIK-6，TWIK-7，IC23927，TWIK-8，IC47611，IC47615，HNMDA-1，TWIK-9，α2Δ-4,8099， 46455,55414,53763,97076,97102,44181,67084FL和67084alt核酸分子，其编码新的离子通道家族分子，包括钙通道，钾通道和NMDA受体。 本发明还提供反义核酸分子，含有TWIK-6，TWIK-7，IC23927，TWIK-8，IC47611，IC47615，HNMDA-1，TWIK-9，α2Δ- 4,8099,46455,54144,53763,97076,97102,44181,67084FL和67084alt核酸分子，其中引入了表达载体的宿主细胞，以及非人转基因动物，其中TWIK-6，TWIK-7 ，IC23927，TWIK-8，IC47611，IC47615，HNMDA-1，TWIK-9，α2Δ-4,8099,46455,5414,53763,97076,97102,44181,67084FL和67084alt基因 已被引入或中断。 本发明还进一步提供了分离的TWIK-6，TWIK-7，IC23927，TWIK-8，IC47611，IC47615，HNMDA-1，TWIK-9，α2ΔΔ4,8099,46455,5444 ，53763,97076,97102,44181,67084FL和67084alt多肽，融合多肽，抗原肽和抗TWIK-6，TWIK-7，IC23927，TWIK-8，IC47611，IC47615，HNMDA-1，TWIK-9， 3Δ-4，8099,46455,5414,53763,97076,97102,44181,67084FL和67084alt抗体。 还提供了利用本发明组合物的诊断和治疗方法。
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.052 秒)
